Electrolyte and protein imbalance following anti-EGFR therapy in cancer patients: A comparative study

Experimental and Therapeutic Medicine

Volumn 1, Issue 2, 2010, Pages 307-311

  Maliakal, Pius ^a   Ledford, Andrea ^a  

^a M D ANDERSON CANCER CENTER ORLANDO   (United States)

Author keywords

Cetuximab; Electrolytic changes; Epidermal growth factor receptor inhibitors; Hypoalbuminemia; Hypocalcemia; Hypomagnesemia; Panitumumab

Indexed keywords

ALBUMIN; CALCIUM; CETUXIMAB; MAGNESIUM; PANITUMUMAB;

ALBUMIN BLOOD LEVEL; ARTICLE; CALCIUM BLOOD LEVEL; CANCER PATIENT; COLORECTAL CANCER; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG WITHDRAWAL; ELECTROLYTE DISTURBANCE; HEAD AND NECK CANCER; HUMAN; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOMAGNESEMIA; MAGNESIUM BLOOD LEVEL; MAJOR CLINICAL STUDY; PROTEIN DEFECT; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

EID: 77956197039     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm_00000047     Document Type: Article

References (27)

1. Hynes NE and Lane HA: ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5: 341-354, 2005.
2. Di Fiore PP, Pierce JH, Fleming TP, et al: Overexpression of the human EGF receptor confers an EGF-dependent transformed phenotype to NIH 3T3 cells. Cell 51: 1063-1070, 1987.
3. Riechmann L, Clark M, Waldmann H and Winter G: Reshaping human antibodies for therapy. Nature 332: 323-327, 1988.
4. Baselga J, Pfister D, Cooper MR, et al: Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 18: 904-914, 2000.
5. Robert F, Ezekiel MPMP, Spencer SA, et al: Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 19: 3234-3243, 2001.
6. Peeters M, Balfour J and Arnold D: Review article: panitumumab - a fully human anti-EGFR monoclonal antibody for treatment of metastatic colorectal cancer. Aliment Pharmacol Ther 28: 269-281, 2008.
7. Lynch DH and Yang XD: Therapeutic potential of ABX-EGF: a fully human anti-epidermal growth factor receptor monoclonal antibody for cancer treatment. Semin Oncol 29: 47-50, 2002.
8. Schrag D, Chung KY, Flombaum C and Saltz L: Cetuximab therapy and symptomatic hypomagnesemia. J Natl Cancer Inst 97: 1221-1224, 2005.
9. Van Cutsem E, Siena S, Humblet Y, et al: An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy. Ann Oncol 19: 92-98, 2008.
10. Tejpar S, Piessevaux H, Claes K, et al: Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study. Lancet Oncol 8: 387-394, 2007.
11. Fakih M: Management of anti-EGFR-targeting monoclonal antibody-induced hypomagnesemia. Oncology 22: 74-76, 2008.
12. Sobrero A, Fehrenbacher L and Rivera F: Randomized phase III trial of cetuximab plus irinotecan versus irinotecan alone for metastatic colorectal cancer in 1298 patients who have failed prior oxaliplatin-based therapy. Program and abstracts of the American Association for Cancer Research Annual Meeting, Los Angeles, April 2007.
13. Van Cutsem E, Nowacki M and Lang I: Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): the CRYSTAL trial. Program and abstracts of the American Association for Cancer Research Annual Meeting, Los Angeles, April 2007.
14. Konrad M, Schlingmann KP and Gudermann T: Insights into the molecular nature of magnesium homeostasis. Am J Physiol Renal Physiol 286: F599-F605, 2004.
15. 2+ channels in health and disease. J Am Soc Nephrol 16: 15-26, 2005.
16. 2+ absorption. J Biol Chem 279: 19-25, 2004.
17. Gesualdo L, Di Paolo S, Calabro A, et al: Expression of epidermal growth factor and its receptor in normal and diseased human kidney: an immunohistochemical and in situ hybridization study. Kidney Int 49: 656-665, 1996.
18. Sack E and Talor Z: High affinity binding sites for epidermal growth factor (EGF) in renal membranes. Biochem Biophys Res Commun 154: 312-317, 1988.
19. Groenestege WM, Thebault S, van der Wijst J, et al: Impaired basolateral sorting of pro-EGF causes isolated recessive renal hypomagnesemia. J Clin Invest 117: 2260-2267, 2007.
20. Schlingmann KP, Weber S, Peters M, et al: Hypomagnesemia with secondary hypocalcemia is caused by mutations in TRPM6, a new member of the TRPM gene family. Nat Genet 31: 166-170, 2002.
21. Knaus WA, Wagner DP, Draper EA, et al: The APACHE III prognostic system. Risk prediction of hospital mortality for critically ill hospitalized adults. Chest 100: 1619-1636, 1991.
22. Lis CG, Grutsch JF, Vashi PG and Lammersfeld CA: Is serum albumin an independent predictor of survival in patients with breast cancer? JPEN J Parenter Enteral Nutr 27: 10-15, 2003.
23. Seaton K: Albumin, cancer and pregnancy. J Natl Med Assoc 94: 629-630, 2002.
24. Gobbi PG, Gendarini A, Crema A, et al: Serum albumin in Hodgkin's disease. Cancer 55: 389-393, 1985.
25. Emerson TE Jr: Unique features of albumin: a brief review. Crit Care Med 17: 690-694, 1989.
26. Peters T: All about albumin. New York Academic Press, New York, 1996.
27. Seaton K: Albumin concentration controls cancer. J Natl Med Assoc 93: 490-493, 2001.